EFFICACY OF HYBRID THERAPY (RA-RACM) IN PATIENTS WITH HELICOBACTER PYLORI POSITIVE-CHRONIC GASTRITIS

Abstract

Objectives: To evaluate the efficacy and adverse effects of hybrid regime in patients with chronic gastritis patients H.pylori positive. Subjects and methods: A prospective cross-sectional study was conducted on 189 chronic gastritis patients at Cho Ray Hospital, from 25/09/2013 to 29/07/2014. All patients underwent upper gastrointestinal endoscopy and biopsy to perform CLO Test and analyse histo-pathological. 92 patients H.pylori with CLO test positive were enrolled in the therapy with hybrid therapy RA-RACM. Results: 92 patients with positive H.pylori (36 males and 56 females), the mean age of population study was 41.65 ± 11.69. The percentage of H.pylori infection was 48.7. The eradication rate of H.pylori was 88.0%. In general, comparison of before and after eradication, the prevalence of epigastric pain was 89.1% vs. 69.1%, delayed gastric empty and sour reflux and the other clinical symptoms were 61.9% vs. 30.8%, 46.7% vs. 30.8% and 31.5% vs. 4.9%, respectively (p < 0.05). Endoscopically, after H.pylori eradication: congestive antritis (from 53.2% to 63.1%), raised erosion (from 15.2% to 14.1%), flat erosion (from 31.5% to 22.8%) (p > 0.05). Histopathology, before H.pylori eradication: Antral active gastritis (61.9%), atrophic gastritis (13.0%), intestinal metaplasia (6.5%), dysplasia (5.4%). Corpus active gastritis (59.8%), atrophic gastritis (5.4%), intestinal metaplasia (2.2%), dysplasia (4.3%); (p> 0.05). Most of lesions were mild. The rate of H.pylori infection in antrum (33.9%), and in corpus (28.0%). The most common adverse effects were 70.6%, mainly bitter taste, none of patients was excluded. Conclusions: The eradication rate of hybrid regime (RA-RACM) is high; the side effects were rare and relatively mild. Hybrid therapy may be considered as a first line of H.pylori treatment in current clinical practice. Key words: Chronic gastritis, hybrid regime (RA-RACM), H.pylori